Chelsea scored FDA approval for Northera, but the launch is no sure bet

Chelsea Therapeutics' ($CHTP) antidizziness drug Northera finally came out a winner at the FDA, securing approval to fight faintness in patients with a rare disorder. But success is not guaranteed: The approval came with a daunting label and some strings attached. Report

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.